With the rapid acceleration of telehealth solutions brought about by the pandemic, one company is uniquely servicing a key demographic- expectant mothers. Medtech HeraMED (ASX: HMD) is moving obstetric care into 2021 with their comprehensive digital health platform, HeraCARE and associated fetal and maternal heart rate monitor, HeraBEAT. The clinically validated tech allows for remote
Read MoreBringing telehealth to expectant mothers that will rival major hospital facilities, medtech company HeraMED (ASX: HMD) is taking a significant step forward in the commercialisation of their foetal monitoring device. As part of their Technology as a Service (TaaS) recurring revenue model, the Company has entered into an agreement with Joondalup Health Campus (JHC) which
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.